1. P1134: OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA POST-CBTK INHIBITOR THERAPY IN THE UNITED STATES AND JAPAN: A STUDY OF TWO REAL-WORLD DATABASES. (23rd June 2022) Authors: Rai, S.; Hess, L.; Chen, Y.; Abada, P.; Konig, H.; Walgren, R.; Tanizawa, Y.; Cai, Z.; Tajimi, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1024 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. (August 2018) Authors: Berdeja, J.; Palandri, F.; Baer, M.R.; Quick, D.; Kiladjian, J.J.; Martinelli, G.; Verma, A.; Hamid, O.; Walgren, R.; Pitou, C.; Li, P.L.; Gerds, A.T. Journal: Leukemia research Issue: Volume 71(2018) Page Start: 82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗